Loading clinical trials...
Loading clinical trials...
A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine Intensive Care Patients
Conditions
Interventions
IC43
Placebo
Locations
50
Austria
LKH - University Clinic Graz
Graz, Graz, Austria
LKH Salzburg
Salzburg, Salzburg, Austria
Medical University of Vienna
Vienna, Vienna, Austria
Otto Wagner Spital
Vienna, Vienna, Austria
Wilhelminenspital & Kaiserin-Elisabeth-Spital
Vienna, Vienna, Austria
Krankenhaus Hietzing
Vienna, Austria
Start Date
March 1, 2012
Primary Completion Date
August 1, 2015
Completion Date
December 1, 2015
Last Updated
March 31, 2016
NCT06319235
NCT01315678
Lead Sponsor
Valneva Austria GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions